Specificity, synergy, and mechanisms of splice-modifying drugs

Yuma Ishigami,Mandy S. Wong,Carlos Martí-Gómez,Andalus Ayaz,Mahdi Kooshkbaghi,Sonya M. Hanson,David M. McCandlish,Adrian R. Krainer,Justin B. Kinney

DOI: https://doi.org/10.1038/s41467-024-46090-5

IF: 16.6

2024-02-29

Nature Communications

Abstract:Abstract Drugs that target pre-mRNA splicing hold great therapeutic potential, but the quantitative understanding of how these drugs work is limited. Here we introduce mechanistically interpretable quantitative models for the sequence-specific and concentration-dependent behavior of splice-modifying drugs. Using massively parallel splicing assays, RNA-seq experiments, and precision dose-response curves, we obtain quantitative models for two small-molecule drugs, risdiplam and branaplam, developed for treating spinal muscular atrophy. The results quantitatively characterize the specificities of risdiplam and branaplam for 5’ splice site sequences, suggest that branaplam recognizes 5’ splice sites via two distinct interaction modes, and contradict the prevailing two-site hypothesis for risdiplam activity at SMN2 exon 7. The results also show that anomalous single-drug cooperativity, as well as multi-drug synergy, are widespread among small-molecule drugs and antisense-oligonucleotide drugs that promote exon inclusion. Our quantitative models thus clarify the mechanisms of existing treatments and provide a basis for the rational development of new therapies.

multidisciplinary sciences

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the lack of quantitative understanding of how splice - modifying drugs act on precursor mRNA splicing. Specifically, the paper presents a quantitatively model with interpretable mechanisms that can explain the sequence - and concentration - dependent behaviors of splice - modifying drugs. The research mainly focuses on two small - molecule drugs - risdiplam and branaplam, both of which are developed for the treatment of Spinal Muscular Atrophy (SMA). ### Main research questions: 1. **Drug specificity**: - Quantitatively characterize the specificity of risdiplam and branaplam for the 5' splice site (5'ss) sequence. - Explain why branaplam recognizes the 5'ss differently from risdiplam and why branaplam is less specific than risdiplam. 2. **Drug mechanism of action**: - Verify and challenge the existing two - site hypothesis, that is, risdiplam promotes the inclusion of exon 7 of SMN2 by binding to two RNA sites. - Propose that branaplam recognizes the 5'ss through two different interaction modes. 3. **Drug synergy**: - Study the abnormal synergy of single drugs and the synergy between multiple drugs, especially in promoting exon inclusion. ### Research methods: - **Massively Parallel Splicing Assays (MPSAs)**: Used to measure the effects of risdiplam and branaplam on variant 5'ss sequences. - **RNA - seq**: Used to evaluate the effects of drugs on splicing across the whole genome. - **Dose - response curves**: Used to accurately measure the dose - effect relationships of drugs. - **Biophysical modeling**: Propose a two - interaction - mode model to explain how branaplam interacts with the 5'ss through two different modes. ### Main findings: - **Specificity of risdiplam**: The specificity of risdiplam for the 5'ss can be described by an IUPAC motif (ANGA/GUHDNN). - **Specificity of branaplam**: The specificity of branaplam for the 5'ss cannot be described by a single IUPAC motif, but requires a two - IUPAC - motif model, where one motif is the same as that of risdiplam and the other motif (NAGA/GUNNNN) describes the hyper - activated 5'ss. - **Drug mechanism of action**: The research results refute the two - site hypothesis of risdiplam on exon 7 of SMN2 and propose a new explanation. - **Drug synergy**: Abnormal synergy of single drugs and extensive synergy between multiple drugs are discovered. Through these studies, the paper not only clarifies the mechanism of action of existing therapeutic drugs, but also provides a theoretical basis for the development of new treatment methods.

Specificity, synergy, and mechanisms of splice-modifying drugs

Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy

The diversity of splicing modifiers acting on A-1 bulged 5′-splice sites reveals rules for rational drug design

Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers

Recognition of single-stranded nucleic acids by small-molecule splicing modulators

RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides

CRISPR-dCas13d-based deep screening of proximal and distal splicing-regulatory elements

Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene

The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action.

Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy

Atomic-Level Mechanism of Pre-mRNA Splicing in Health and Disease

From computational models of the splicing code to regulatory mechanisms and therapeutic implications

CRISPR-Mediated Enzyme Fragment Complementation Assay for Quantification of the Stability of Splice Isoforms

A Sequential Binding Mechanism for 5’ Splice Site Recognition and Modulation for the Human U1 snRNP

One-Size-Fits-Many: Antisense oligonucleotides for rescuing splicing mutations in hotspot exons

Steering research on mRNA splicing in cancer towards clinical translation

The human splicing code reveals new insights into the genetic determinants of disease

Regulation of pre-mRNA splicing: roles in physiology and disease, and therapeutic prospects

Development and validation of AI/ML derived splice-switching oligonucleotides

Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression